Table 1.

Characteristics of AML patients

Patient no.AgeFABPrognosis/karyotypeMajor abnormalityWBC, *109/LBM blasts (%)FLT3-ITDp-H2AXp-CHK1/CHK1
1682IP/normalNdNd0.8
2381IP/normal85.5901.41.2
3542IP/normal1.5241.6
4515HP/simplet(6;11)MLL-AF6193.2891.7
5701IP/normal174.2911.9
6531IP/normal204.890+1.90.5
7522HP/highly complex (7 ab)5q-, -72.4351.9
8372IP/normal10.043+1.90.7
9731HP/complex (3 ab)7q-84.6801.91.0
10614HP/complex (3 ab)t(7;11)/NUP98-HOXA997602.10.4
11484IP/normal82.965+2.10.6
12434IP/normal64.490+2.2
13591IP/normal125.097+2.30.2
14561IP/normal15.683+2.51.1
15792HP/highly complex (6 ab)5q-, 7q-, -171.9722.81.2
16771IP/normal195.0982.90.7
17611IP/normal9.6902.90.6
18724IP/normal98.1842.9
19215IP/normal226.395+3.10.4
20811IP/normal102.4823.10.3
21371IP/simplet(9;11)/MLL-AF931.690+3.1
22341IP/simple7q-81.893Nd3.40.4
23291IP/normal90.0903.40.5
24344FPCBF176.3853.51.0
25771HP/simplet(11;22)/MLL-p3004.2903.50.4
26722HP/highly complex (12 ab)3q26/EVI1, 5q-,-7,-1718.9563.60.9
27632IP/simple11q-4.5713.60.5
28331HP/highly complex (5 ab)t(10;11)/CALM-AF10, 17p-36963.81.0
29704IP/normal28523.90.3
30764IP/simplet(7;12)/ETV6+49.8654.20.5
31571IP/normal5.6914.22.2
32604IP/simple (2 ab)133.290+4.3
33212IP/normal5.424+4.3
34681IP/normal37.695+4.40.3
35755IP/normal89.7934.5
36791IP/normal172.792+4.80.4
37641IP/normal182.494+4.90.5
38770HP/simple5q-67.890Nd5.4
39195HP/highly complex (13 ab)5q-,17p-,+815.2615.61.0
40821HP/highly complex (4 ab)3q26/EVI1,7q-,amplif MLL146.7865.61.0
41622HP/complex (3 ab)20q-29.8486.11.7
42760HP/highly complex (6 ab)5q-,-7,-1770846.71.9
43764IP/simple136.0926.8
4495HP/simplet(1;11)/MLL-AF1p41.7946.91.2
45532HP/simple5q-33.2798.00.3
46794IP/normal104.0588.0
47482FPCBF6.2488.8
48692HP/complex (3 ab)5q-,amplif MLL1.23015.50.9
49755IP/normal252.895+8.20.2
50505IP/simple32697Nd9.8

NOTE: Prognosis factor groups were established according the classification of Grimwade and Schlenk on the basis of the cytogenesis analysis (3, 4).

Abbreviations: FAB, French-American-British classification; WBC, white blood cell count; FLT3-ITD, FLT3-internal tandem duplication; FP, favorable prognosis; IP, intermediate prognosis; HP, high-risk prognosis; ab, abnormalities; Nd, not done.